Search

Geron Corp

Closed

SectorHealthcare

1.43

Overview

Share price change

24h

Current

Min

1.41

Max

1.47

Key metrics

By Trading Economics

Income

25M

-3.6M

Sales

3.8M

52M

EPS

-0.005

Profit margin

-7.026

Employees

258

EBITDA

27M

3.8M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+177.78% upside

Dividends

By Acuity

Next Earnings

5 sie 2026

Market Stats

By TradingEconomics

Market Cap

-44M

962M

Previous open

1.43

Previous close

1.43

News Sentiment

By Acuity

85%

15%

315 / 340 Ranking in Healthcare

Geron Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 lip 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

177.78% upside

12 Months Forecast

Average 4 USD  177.78%

High 5 USD

Low 3 USD

Based on 4 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Sentiment

By Acuity

315 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat